TNSN07037A1 - Proteines de fusion de rage et methodes d'utilisation - Google Patents

Proteines de fusion de rage et methodes d'utilisation

Info

Publication number
TNSN07037A1
TNSN07037A1 TNP2007000037A TNSN07037A TNSN07037A1 TN SN07037 A1 TNSN07037 A1 TN SN07037A1 TN P2007000037 A TNP2007000037 A TN P2007000037A TN SN07037 A TNSN07037 A TN SN07037A TN SN07037 A1 TNSN07037 A1 TN SN07037A1
Authority
TN
Tunisia
Prior art keywords
rage
fusion proteins
methods
rage fusion
domain
Prior art date
Application number
TNP2007000037A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Ye E Tian
Jeffrey C Webster
Robert Rothlein
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of TNSN07037A1 publication Critical patent/TNSN07037A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)

Abstract

Il est décrit des protéines de fusion de RAGE, comprenant des séquences de polypeptide RAGE liées à un second polypeptide non RAGE. La protéine de fusion de RAGE peut utiliser un domaine de polypeptide RAGE comprenant un site de liaison de ligand de RAGE et un segment de liaison interdomaine lié directement à un domaine Ch2 d'immunoglobuline. Ces protéines de fusion peuvent présenter une liaison spécifique à forte affinité à des ligands de RAGE. Il est également décrit l'utilisation de protéines de fusion de RAGE comme agents thérapeutiques pour des pathologies à médiation par RAGE.
TNP2007000037A 2004-08-03 2007-02-02 Proteines de fusion de rage et methodes d'utilisation TNSN07037A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59855504P 2004-08-03 2004-08-03
PCT/US2005/027705 WO2006017647A1 (fr) 2004-08-03 2005-08-03 Protéines hybrides rage et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
TNSN07037A1 true TNSN07037A1 (fr) 2008-06-02

Family

ID=35149359

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000037A TNSN07037A1 (fr) 2004-08-03 2007-02-02 Proteines de fusion de rage et methodes d'utilisation

Country Status (23)

Country Link
US (5) US7981423B2 (fr)
EP (1) EP1781700B1 (fr)
JP (1) JP5188804B2 (fr)
KR (1) KR101323411B1 (fr)
CN (1) CN1993378A (fr)
AP (1) AP2007003869A0 (fr)
AU (1) AU2005271452B2 (fr)
BR (1) BRPI0514052A (fr)
CA (1) CA2570324C (fr)
CR (1) CR20110556A (fr)
EA (1) EA012082B1 (fr)
EC (1) ECSP077221A (fr)
ES (1) ES2473587T3 (fr)
GE (1) GEP20105110B (fr)
IL (1) IL180554A (fr)
MA (1) MA29067B1 (fr)
MX (1) MX2007001559A (fr)
NO (1) NO20065949L (fr)
NZ (1) NZ552128A (fr)
TN (1) TNSN07037A1 (fr)
UA (1) UA93356C2 (fr)
WO (1) WO2006017647A1 (fr)
ZA (2) ZA200700643B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006017643A1 (fr) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Protéines de fusion récepteurs de type rage et procédés d'utilisation de celles-ci
WO2006119510A2 (fr) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
US7957931B2 (en) * 2005-12-23 2011-06-07 Gcoder Systems Ab Positioning pattern
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
EP2380983A3 (fr) * 2006-05-05 2012-12-05 TransTech Pharma Inc. Protéines de fusion RAGE, formulations et procédés d'utilisation correspondants
EP2423222B2 (fr) 2007-01-30 2020-07-29 Epivax, Inc. Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
WO2008153957A1 (fr) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Utilisation d'antagonistes de rage pour le traitement de l'obésité et de maladies associées
RU2513695C2 (ru) * 2007-06-14 2014-04-20 Гэлэктика Фармасьютикалс, Инк. Слитые белки rage
US20120047586A9 (en) * 2007-10-24 2012-02-23 Otsuka Chemical Co., Ltd Polypeptide having enhanced effector function
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
KR20120127543A (ko) 2008-05-23 2012-11-21 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치
CA2757079C (fr) 2009-04-20 2015-05-19 Pfizer Inc. Controle de la glycosylation de proteines, compositions et methodes associees
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011102845A1 (fr) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Compositions de protéines de fusion rage et méthodes d'utilisation
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IN2013MN02441A (fr) 2011-06-28 2015-06-12 Inhibrx Llc
KR20140068861A (ko) 2011-06-28 2014-06-09 인히브릭스 엘엘씨 Wap 도메인 융합 폴리펩티드 및 이의 이용 방법
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
WO2015023165A1 (fr) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 Composite de régulation d'une inflammation et cellules souches mésenchymateuse stabilisées ayant une fonction optimisée de régulation de l'immunité par blocage de la molécule de signalisation stat3
MX2017003565A (es) 2014-09-19 2017-07-14 Siwa Corp Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
AU2017219749B2 (en) 2016-02-19 2022-01-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
WO2017181116A1 (fr) 2016-04-15 2017-10-19 Siwa Corporation Anticorps anti-age pour le traitement de troubles neurodégénératifs
EP3470424A4 (fr) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine Séquence de région constante à chaîne lourde d'anticorps pour améliorer l'activité d'anticorps agonistes
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
EP3583119A2 (fr) * 2017-02-17 2019-12-25 Denali Therapeutics Inc. Polypeptides modifiés
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3849578A4 (fr) 2018-09-14 2022-06-22 Bioage Labs, Inc. Protéines de fusion rage présentant une stabilité et une affinité de liaison aux ligands améliorées et leurs utilisations

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
NO315930B1 (no) 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
WO1996022095A2 (fr) 1995-01-18 1996-07-25 Alteon Inc. Utilisation de composes de thiazolium pour empecher et inverser la formation de produits finis de glycosylation avancee
AU5386996A (en) 1995-04-05 1996-10-23 Picower Institute For Medical Research, The Agents for binding to advanced glycosylation endproducts, an d methods of their use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO2000020621A1 (fr) 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Nouvelle proteine extracellulaire liant le peptide rage (en-rage), et utilisations correspondantes
US7081241B1 (en) 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
JP2001514661A (ja) 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
EP1307219A4 (fr) 1999-08-13 2005-04-06 Univ Columbia Procedes d'inhibition de la liaison de la fibrille a feuillets beta au recepteur rage, et leurs consequences
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
US20050170382A1 (en) 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
EP1287162A2 (fr) 1999-10-21 2003-03-05 Case Western Reserve University Profilage de l'expression genetique d'une affection intestinale inflammatoire
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
AU5355501A (en) * 2000-04-14 2001-10-30 Niadyne Corp Method for identifying regulators of protein-advanced glycation end product (protein-age) formation
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
CA2408253A1 (fr) 2000-05-09 2001-11-15 Genetics Institute, Llc Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie du psoriasis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
AU2001283138A1 (en) * 2000-08-07 2002-02-18 Amberwave Systems Corporation Gate technology for strained surface channel and strained buried channel mosfet devices
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
CA2424246A1 (fr) * 2000-10-02 2002-04-11 Shianlen Cahoon Methodes et compositions pour traiter des maladies inflammatoires
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
EP1368648A2 (fr) * 2000-12-29 2003-12-10 Reddy US Therapeutics, Inc. Detection de composes modulateurs de reponses inflammatoires
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
DE10109466B4 (de) 2001-02-28 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
DK1370571T3 (da) * 2001-03-22 2005-10-17 Vlaams Interuniv Inst Biotech Fremgangsmåde og apparat til gelfri kvalitativ og kvantitativ proteomanalyse samt anvendelser deraf
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
IL166157A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
BR0313491A (pt) * 2002-08-16 2007-08-14 Wyeth Corp composições e métodos para tratar distúrbios associados ao rage
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EP1578797A1 (fr) 2002-12-13 2005-09-28 Licentia Ltd. Proteine transmembranaire amigo et utilisations de celle-ci
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005023191A2 (fr) 2003-09-05 2005-03-17 The Trustees Of Columbia University In The City Of New York Procedes et compositions associes aux produits terminaux de la glycation avancee pour le traitement de la lesion glomerulaire
WO2005042032A1 (fr) 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Procedes pour traiter la sclerose en plaques
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
WO2005051995A2 (fr) 2003-11-19 2005-06-09 Curagen Corporation Nouvelle proteine de type recepteur specifique au produit d'extremite d'une glycosylation avancee et acides nucleiques codant cette proteine
GB0330079D0 (en) 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
CN100342017C (zh) 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
AU2005259381A1 (en) 2004-07-02 2006-01-12 Creabilis Therapeutics S.P.A. Nucleic acids for the treatment of HMGB1-related pathologies
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
EP1814576A2 (fr) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Therapie contre l'inflammation combinant le hmgb et les inhibiteurs du complement
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
WO2006017643A1 (fr) 2004-08-03 2006-02-16 Transtech Pharma, Inc. Protéines de fusion récepteurs de type rage et procédés d'utilisation de celles-ci
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
EP1799700A4 (fr) 2004-09-27 2009-02-11 Centocor Inc Corps mimetiques srage, compositions, et methodes d'utilisation
WO2006119510A2 (fr) 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci
US20080207499A1 (en) 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
US20090004190A1 (en) 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
EP2380983A3 (fr) * 2006-05-05 2012-12-05 TransTech Pharma Inc. Protéines de fusion RAGE, formulations et procédés d'utilisation correspondants
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
WO2008100470A2 (fr) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
RU2513695C2 (ru) 2007-06-14 2014-04-20 Гэлэктика Фармасьютикалс, Инк. Слитые белки rage

Also Published As

Publication number Publication date
CA2570324C (fr) 2014-07-22
AU2005271452A1 (en) 2006-02-16
ECSP077221A (es) 2007-03-29
KR20070039981A (ko) 2007-04-13
CA2570324A1 (fr) 2006-02-16
ES2473587T3 (es) 2014-07-07
AU2005271452B2 (en) 2011-11-03
EA012082B1 (ru) 2009-08-28
ZA200700643B (en) 2010-07-28
NZ552128A (en) 2009-09-25
MA29067B1 (fr) 2007-12-03
GEP20105110B (en) 2010-11-10
US7901688B2 (en) 2011-03-08
US20110124102A1 (en) 2011-05-26
US20060030527A1 (en) 2006-02-09
EA200700404A1 (ru) 2007-06-29
US20120171202A1 (en) 2012-07-05
CR20110556A (es) 2011-11-10
KR101323411B1 (ko) 2013-10-30
NO20065949L (no) 2007-01-16
US8877192B2 (en) 2014-11-04
JP5188804B2 (ja) 2013-04-24
US7981423B2 (en) 2011-07-19
JP2008512988A (ja) 2008-05-01
US20080075733A1 (en) 2008-03-27
AP2007003869A0 (en) 2007-02-28
IL180554A (en) 2013-09-30
EP1781700B1 (fr) 2014-03-19
IL180554A0 (en) 2007-06-03
US20110244516A1 (en) 2011-10-06
CN1993378A (zh) 2007-07-04
EP1781700A1 (fr) 2007-05-09
MX2007001559A (es) 2007-04-10
UA93356C2 (ru) 2011-02-10
ZA200906459B (en) 2010-05-26
BRPI0514052A (pt) 2008-05-27
WO2006017647A1 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
TNSN07037A1 (fr) Proteines de fusion de rage et methodes d'utilisation
TNSN07040A1 (fr) Proteines de fusion de rage et methodes d'utilisation
EA200870502A1 (ru) Белки слияния на основе rage, их композиции и способы их применения
WO2007094926A3 (fr) Protéines hybrides rage et leurs procédés d'utilisation
Strickland et al. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor.
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
KR930703008A (ko) 복합된 특이성 융합 단백질
WO2006038027A3 (fr) Antagonistes et leurs methodes d'utilisation
MXPA06001225A (es) Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
WO2003033654A3 (fr) Proteines de liaison de ciblage direct
EA200800696A1 (ru) Полипептиды и антитела
MA32449B1 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
DE602005021072D1 (de) Adzyme und deren verwendungen
ATE394485T1 (de) Neue g protein-gekoppelte rezeptor proteine, dnas davon und liganden für diese
DE60111733D1 (de) Integrinbindende peptidderivate
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
Lubbers et al. Carbamylation reduces the capacity of IgG for hexamerization and complement activation
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
AU2003288810A1 (en) Peptides that bind to the heparin binding domian of vegf and vegfr-2
Villegas‐Mendez et al. Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3
Wu et al. Receptors specific for Amadori-modified glycated albumin on murine endothelial cells
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
WO2005072380A3 (fr) Complexes d'attaque de membrane associees aux complexes immunitaires de circulation
DE69909312D1 (de) Methoden zur identifizierung von "hot-spot" resten bindender proteine und kleine verbindungen die an diese binden